A Double-Blind, Randomized, Placebo-Controlled Efficacy and Safety Study of DVS-233 SR for Treatment of Vasomotor Symptoms Associated With Menopause

Trial Profile

A Double-Blind, Randomized, Placebo-Controlled Efficacy and Safety Study of DVS-233 SR for Treatment of Vasomotor Symptoms Associated With Menopause

Completed
Phase of Trial: Phase III

Latest Information Update: 26 Mar 2009

At a glance

  • Drugs Desvenlafaxine (Primary)
  • Indications Hot flashes; Menopausal syndrome; Menopause; Vasomotor symptoms
  • Focus Therapeutic Use
  • Most Recent Events

    • 01 Jan 2008 Results have been reported.
    • 11 May 2007 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top